๐ ๐ป
๐น Asset: CRISPR Therapeutics AG (CRSP โ NASDAQ)
๐น Timeframe: 30-Min Chart
๐น Setup Type: Bearish Pennant Breakdown + Retest Rejection
๐ Trade Plan (Short Position)
โ Entry Zone: Below $31.30 (Confirmed Breakdown)
โ Stop-Loss (SL): Above $33.58 (White Resistance Level)
๐ฏ Take Profit Targets:
๐ TP1: $28.56 (Mid-support zone)
๐ TP2: $25.61 (Key demand area)
๐ Risk-Reward Ratio Calculation
๐ Risk (SL Distance):
$33.58 - $31.30 = $2.28 risk per share
๐ Reward to TP1:
$31.30 - $28.56 = $2.74 โ R/R = 1:1.20
๐ Reward to TP2:
$31.30 - $25.61 = $5.69 โ R/R = 1:2.49
๐ Technical Analysis & Strategy
๐ Bearish Pennant Breakdown: Price broke the pattern and is now rejecting the yellow zone on a retest.
๐ Lower Highs + Breakdown Structure: Indicates weakness, confirming bearish bias.
๐ Support Levels Below: Room to fall towards multiple levels of structure.
๐ Volume Check: Look for continued weak volume on bounce to confirm lack of demand.
๐ Trade Execution & Risk Management
๐ Entry Trigger: Break and hold below $31.30 with weak bullish reaction.
๐ Trailing Stop Strategy: Move SL to breakeven once TP1 is hit.
๐ฐ Partial Profit Booking:
โ Close 50% position at $28.56
โ Let remaining ride toward $25.61
โ Adjust SL to breakeven after TP1
โ ๏ธ Setup Invalidation
โ Strong bullish reversal candle with volume above $33.58
โ Consolidation above yellow zone after false breakdown
โ Positive news or catalyst reversing trend
๐จ Final Thoughts
โ Clean breakdown pattern with confluence resistance at $33.58
โ Bearish trend intact with lower highs and breakdowns
โ High probability setup with strong R/R potential
๐ก Stick to the plan, manage risk, and let the chart do the talking.
๐ #CRSP #OptionsTrading #NASDAQStocks #TradingSetup #BearishTrade #ProfittoPath #SwingTradeSetup #RiskReward #ChartAnalysis #TradingView
๐น Asset: CRISPR Therapeutics AG (CRSP โ NASDAQ)
๐น Timeframe: 30-Min Chart
๐น Setup Type: Bearish Pennant Breakdown + Retest Rejection
๐ Trade Plan (Short Position)
โ Entry Zone: Below $31.30 (Confirmed Breakdown)
โ Stop-Loss (SL): Above $33.58 (White Resistance Level)
๐ฏ Take Profit Targets:
๐ TP1: $28.56 (Mid-support zone)
๐ TP2: $25.61 (Key demand area)
๐ Risk-Reward Ratio Calculation
๐ Risk (SL Distance):
$33.58 - $31.30 = $2.28 risk per share
๐ Reward to TP1:
$31.30 - $28.56 = $2.74 โ R/R = 1:1.20
๐ Reward to TP2:
$31.30 - $25.61 = $5.69 โ R/R = 1:2.49
๐ Technical Analysis & Strategy
๐ Bearish Pennant Breakdown: Price broke the pattern and is now rejecting the yellow zone on a retest.
๐ Lower Highs + Breakdown Structure: Indicates weakness, confirming bearish bias.
๐ Support Levels Below: Room to fall towards multiple levels of structure.
๐ Volume Check: Look for continued weak volume on bounce to confirm lack of demand.
๐ Trade Execution & Risk Management
๐ Entry Trigger: Break and hold below $31.30 with weak bullish reaction.
๐ Trailing Stop Strategy: Move SL to breakeven once TP1 is hit.
๐ฐ Partial Profit Booking:
โ Close 50% position at $28.56
โ Let remaining ride toward $25.61
โ Adjust SL to breakeven after TP1
โ ๏ธ Setup Invalidation
โ Strong bullish reversal candle with volume above $33.58
โ Consolidation above yellow zone after false breakdown
โ Positive news or catalyst reversing trend
๐จ Final Thoughts
โ Clean breakdown pattern with confluence resistance at $33.58
โ Bearish trend intact with lower highs and breakdowns
โ High probability setup with strong R/R potential
๐ก Stick to the plan, manage risk, and let the chart do the talking.
๐ #CRSP #OptionsTrading #NASDAQStocks #TradingSetup #BearishTrade #ProfittoPath #SwingTradeSetup #RiskReward #ChartAnalysis #TradingView
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.